A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients

Kidney International

Volumn 88, Issue 6, 2015, Pages 1293-1303

  Weist, Benjamin J D ^a   Wehler, Patrizia ^a   El Ahmad, Linda ^a   Schmueck Henneresse, Michael ^a   Millward, Jason M ^a   Nienen, Mikalai ^a   Neumann, Avidan U ^a   Reinke, Petra ^a   Babel, Nina ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Calcineurin inhibitors; Lymphocytes; Transplantation

Indexed keywords

AZATHIOPRINE; CD137 ANTIGEN; CD40 LIGAND; CYCLOSPORIN A; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; LYMPHOCYTE SURFACE MARKER; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BK VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION; MALE; MIDDLE AGED; NONHUMAN; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REACTIVATION;

EID: 84951569462     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.215     Document Type: Article

References (49)

1. Rubin RH, Snydman D, Harrington JT et al. Infectious-disease complications of renal-transplantation. Kidney Int 1993; 44: 221-236
2. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751
3. Hirsch HH. Polyomavirus BK nephropathy: A (re-)emerging complication in renal transplantation. Am J Transplant 2002; 2: 25-30
4. Hirsch HH, Steiger J, Polyomavirus BK. Lancet Infect Dis 2003; 3: 611-623
5. Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect Dis 2005; 41: 354-360
6. Kwon HJ, Kang JH, Lee JW et al. Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single-center experience. Transpl Infect Dis 2013; 15: 569-574
7. Rinaldo CH, Gosert R, Bernhoff E et al. 1-O-Hexadecyloxypropyl Cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother 2010; 54: 4714-4722
8. Randhawa PS, Finkelstein S, Scantlebury V et al. Human polyoma virusassociated interstitial nephritis in the allograft kidney. Transplantation 1999; 67: 103-109
9. Babel N, Volk HD, Reinke P. BK polyomavirus infection and nephropathy: the virus-immune system interplay. Nat Rev Nephrol 2011; 7: 399-406
10. Schachtner T, Muller K, Stein M et al. BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant 2011; 11: 2443-2452
11. Binggeli S, Egli A, Schaub S et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 2007; 7: 1131-1139
12. Schachtner T, Stein M, Sefrin A et al. Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation. Transpl Int 2013; 27: 290-301
13. Chakera A, Bennett S, Lawrence S et al. Antigen-specific T cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide immunosuppression following renal transplantation. Clin Exp Immunol 2011; 165: 401-409
14. Ramaswami B, Popescu I, Macedo C et al. The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response. Clin Vaccine Immunol 2011; 18: 815-824
15. Trydzenskaya H, Sattler A, Muller K et al. Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. Transplantation 2011; 92: 1269-1277
16. Blyth E, Clancy L, Simms R et al. BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation 2011; 92: 1077-1084
17. Mueller K, Schachtner T, Sattler A et al. BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation 2011; 91: 100-107
18. van Aalderen MC, Remmerswaal EB, Heutinck KM et al. Phenotypic and functional characterization of circulating polyomavirus BK VP1-specific CD8+ T cells in healthy adults. J Virol 2013; 87: 10263-10272
19. Kirchhoff D, Frentsch M, Leclerk P et al. Identification and isolation of murine antigen-reactive T cells according to CD154 expression. Eur J Immunol 2007; 37: 2370-2377
20. Frentsch M, Arbach O, Kirchhoff D et al. Direct access to CD4(+) T cells specific for defined antigens according to CD154 expression. Nat Med 2005; 11: 1118-1124
21. Wolfl M, Kuball J, Ho WY et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007; 110: 201-210
22. Zandvliet ML, van Liempt E, Jedema I et al. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother 2011; 34: 307-319
23. Shuford WW, Klussman K, Tritchler DD et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186: 47-55
24. Egli A, Kohli S, Dickenmann M et al. Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation 2009; 88: 1161-1168
25. Hirsch HH, Vincenti F, Friman S et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant 2013; 13: 136-145
26. Zhou W, Sharma M, Martinez J et al. Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol 2007; 20: 379-388
27. Weist BJ, Schmueck M, Fuehrer H et al. The role of CD4 T cells in BKV-specific T cell immunity. Med Microbiol Immunol 2014; 203: 395-408
28. Sanchez Fructuoso AI, Calvo N, Perez-Flores I et al. Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients. Transpl Infect Dis 2011; 13: 584-591
29. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019-1026
30. Oelke M, Kurokawa T, Hentrich I et al. Functional characterization of CD8(+) antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: comparison with the MHC-tetramer technology. Scand J Immunol 2000; 52: 544-549
31. Brestrich G, Zwinger S, Fischer A et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009; 9: 1679-1684
32. Becker C, Pohla H, Frankenberger B et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7: 1159-1162
33. Zaunders JJ, Dyer WB, Wang B et al. Identification of circulating antigenspecific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood 2004; 103: 2238-2247
34. Appay V, Zaunders JJ, Papagno L et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002; 168: 5954-5958
35. Haigh TA, Lin X, Jia H et al. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol 2008; 180: 1643-1654
36. Landais E, Saulquin X, Scotet E et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 2004; 103: 1408-1416
37. Menter T, Mayr M, Schaub S et al. Pathology of resolving polyomavirusassociated nephropathy. Am J Transplant 2013; 13: 1474-1483
38. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247-258
39. Sallusto F, Lenig D, Forster R et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712
40. Curran MA, Geiger TL, Montalvo W et al. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 2013; 210: 743-755
41. Hammer MH, Brestrich G, Andree H et al. HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am J Transplant 2006; 6: 625-631
42. Babel N, Fendt J, Karaivanov S et al. Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples. Transplantation 2009; 88: 89-95
43. Dong J, Ivascu C, Chang HD et al. IL-10 is excluded from the functional cytokine memory of human CD4+ memory T lymphocytes. J Immunol 2007; 179: 2389-2396
44. Hoffmeister B, Bunde T, Rudawsky IM et al. Detection of antigen-specific T cells by cytokine flow cytometry: the use of whole blood may underestimate frequencies. Eur J Immunol 2003; 33: 3484-3492
45. Schmueck M, Fischer AM, Hammoud B et al. Preferential expansion of human virus-specific multifunctional central memory T cells by partial targeting of the IL-2 receptor signaling pathway: the key role of CD4+ T cells. J Immunol 2012; 188: 5189-5198
46. Hammer MH, Meyer S, Brestrich G et al. HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol 2005; 35: 2250-2258
47. Brestrich G, Zwinger S, Roemhild A et al. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy. J Immunother 2009; 32: 932-940
48. Weist BJ, Schmueck M, Fuehrer H et al. The role of CD4(+) T cells in BKV-specific T cell immunity. Med Microbiol Immunol 2014; 203: 395-408
49. Hermans IF, Silk JD, Yang J et al. The VITAL assay: a versatile fluorometric technique for assessing CTL-and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 2004; 285: 25-40.